Aequus Pharmaceuticals Inc. announced the launch of Zimed® PF, the first preservative-free multi-dose Bimatoprost for glaucoma patients in Canada.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.025 CAD | -16.67% |
|
-16.67% | 0.00% |
1st Jan change | Capi. | |
---|---|---|
0.00% | 2.43M | |
+58.75% | 827B | |
+38.58% | 634B | |
-6.93% | 350B | |
+13.62% | 319B | |
+6.66% | 294B | |
+12.78% | 240B | |
+14.49% | 221B | |
0.00% | 219B | |
+7.43% | 167B |
- Stock Market
- Equities
- AQS Stock
- News Aequus Pharmaceuticals Inc.
- Aequus Pharmaceuticals Inc. Announces Launch of Zimed PF in Canada